Sangeeth M. George

4.5k citations

10 papers · 216 indexed · h-index 5

Co-authors: Lynn M. Schuchter Robert H. Vonderheide Rosemarie Mick E. John Wherry David L. Bajor Matthew J. Riese Xiaowei Xu Erietta Stelekati
Topics: Cancer Immunotherapy and Biomarkers (5 papers)Immunotherapy and Immune Responses (3 papers)Gastrointestinal Tumor Research and Treatment (3 papers)
Cited by: Oncology Immunology Gastroenterology
Journals: Journal of Clinical Oncology Cancer Research British Journal of Cancer
Partner nations: United States United Kingdom

In The Last Decade

Sangeeth M. George

9 papers receiving 214 citations

Peers

Countries citing papers authored by Sangeeth M. George

Since Specialization

Citations

This map shows the geographic impact of Sangeeth M. George's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sangeeth M. George with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sangeeth M. George more than expected).

Fields of papers citing papers by Sangeeth M. George

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sangeeth M. George. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sangeeth M. George. The network helps show where Sangeeth M. George may publish in the future.

Co-authorship network of co-authors of Sangeeth M. George

This figure shows the co-authorship network connecting the top 25 collaborators of Sangeeth M. George. A scholar is included among the top collaborators of Sangeeth M. George based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sangeeth M. George. Sangeeth M. George is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	90 Real world data analysis of neoadjuvant Nivolumab in combination with platinum-based chemotherapy in operable non–small cell lung cancer (NSCLC). The Guy's cancer centre experience 2025 ·Lung Cancer ·(unknown),E. M. Mohammed,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Sangeeth M. George,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	0
2	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours 2018 ·British Journal of Cancer ·Amit Maity,Rosemarie Mick,Alexander C. Huang,Sangeeth M. George,Michael D. Farwell,John N. Lukens,Abigail T. Berman,Tara C. Mitchell,(unknown),Lynn M. Schuchter,Mark H. O’Hara,Lilie L. Lin,Angela DeMichele,John P. Christodouleas,Naomi B. Haas,Dana Patsch,Stephen M. Hahn,Andy J. Minn,E. John Wherry,Robert H. Vonderheide	79
3	Abstract CT181: Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma 2018 ·Cancer Research ·Alexander C. Huang,(unknown),Robert Orlowski,Sangeeth M. George,Lakshmi Chilukuri,Andrew Kozlov,Mary Carberry,Lydia Giles,Suzanne McGettigan,Kristin Kreider,Jennifer H. Yearley,Lakshmanan Annamalai,Gerald P. Linette,Ravi K. Amaravadi,Lynn M. Schuchter,Michael D. Farwell,(unknown),Giorgos C. Karakousis,Tara C. Gangadhar	7
4	A Phase I Trial of Pembrolizumab with Hypofractionated Radiation Therapy (HFRT) in Patients with Metastatic Cancers 2018 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown),Rosemarie Mick,(unknown),Sangeeth M. George,Michael D. Farwell,John N. Lukens,Abigail T. Berman,Tara C. Mitchell,Joshua Bauml,Lynn M. Schuchter,Mark H. O’Hara,Lizhu Lin,A. DeMichele,John P. Christodouleas,Naomi B. Haas,Dana Patsch,(unknown),Andy J. Minn,E. John Wherry,(unknown)	1
5	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma 2018 ·OncoImmunology ·David L. Bajor,Rosemarie Mick,Matthew J. Riese,(unknown),(unknown),Lee P. Richman,Drew A. Torigian,Sangeeth M. George,Erietta Stelekati,Fang Chen,J. Joseph Melenhorst,Simon F. Lacey,Xiaowei Xu,E. John Wherry,Tara C. Gangadhar,Ravi K. Amaravadi,Lynn M. Schuchter,Robert H. Vonderheide	86
6	Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST) 2016 ·European Journal of Cancer ·Michael C. Heinrich,Robin L. Jones,Patrick Schöffski,Sebastian Bauer,Margaret von Mehren,(unknown),(unknown),Olivier Mir,(unknown),(unknown),(unknown),Beni B. Wolf,Sangeeth M. George	4
7	Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors. 2010 ·Journal of Clinical Oncology ·R. Quek,(unknown),Geoffrey I. Shapiro,James E. Butrynski,(unknown),(unknown),(unknown),Amy J. Wagner,G. D. Demetri,Sangeeth M. George	8
8	A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors 2008 ·Journal of Clinical Oncology ·Rohit Lal,D. Ross Camidge,Sangeeth M. George,G. D. Demetri,S. Gail Eckhardt,Andrew Stephens,(unknown),Ramesh Boinpally,Stuart Kaye,Michelle Scurr	2
9	Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors 2005 ·Journal of Clinical Oncology ·T. R. J. Evans,(unknown),Annick D. Van den Abbeele,Iain McPherson,Sangeeth M. George,D. Crawford,(unknown),Shinta Cheng,J. Fletcher,George D. Demetri	26
10	Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy 2005 ·(unknown),David J. McConkey,John V. Heymach,Jayesh Desai,Sangeeth M. George,(unknown),Carlo L. Bello,Charles M. Baum,David R. Shalinsky,(unknown)	3

About Sangeeth M. George

Sangeeth M. George is a scholar working on Gastroenterology, Oncology and Pulmonary and Respiratory Medicine, having authored 10 papers that have together received 216 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), Immunotherapy and Immune Responses (3 papers) and Gastrointestinal Tumor Research and Treatment (3 papers). The work is most often cited by research in Oncology (163 citations), Immunology (105 citations) and Gastroenterology (17 citations). Sangeeth M. George has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Lynn M. Schuchter, Robert H. Vonderheide, Rosemarie Mick, E. John Wherry, David L. Bajor, Matthew J. Riese, Xiaowei Xu, Erietta Stelekati, Ravi K. Amaravadi and Fang Chen. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact